Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 2Other hematologic neoplasm 1

Conditions

Neoplasm Metastasis 1Melanoma 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1

Interventions

Specimen Handling 3Magnetic Resonance Spectroscopy 3trametinib 2dabrafenib 2Palliative Care 2Nivolumab 2Methods 2Ipilimumab 2CTLA-4 Antigen 2Biopsy 2varlilumab 1ulixertinib 1trastuzumab biosimilar HLX02 1temsirolimus 1tanespimycin 1sapanisertib 1romidepsin 1ripretinib 1relatlimab 1pertuzumab 1pembrolizumab 1peginterferon alfa-2a 1palbociclib 1osimertinib 1omipalisib 1larotrectinib 1ipatasertib 1fludarabine 1erdafitinib 1entrectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × GSK2141795 × Other hematologic neoplasm × Clear all
NCT01902173 2025-01-14

Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
27 enrolled 16 charts
DermatologicOther hematologic neoplasm

Melanoma, Neoplasm Metastasis, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡